'Lenvatinib represents a paradigm shift in the treatment of advanced thyroid cancer, and will bring new options to patients and clinicians,' said Martin Schlumberger, primary investigator and Professor of Oncology at the Institut Gustave Roussy, University Paris Sud. 'Clinicians will be excited to prescribe a treatment with significant benefits in progression-free survival.'
Results of EXAM were presented by Martin Schlumberger, MD, of Institut Gustave Roussy in Villejuif, France, and colleagues as a poster presentation at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting held May 29 to June 2 in Chicago.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.